SCHEMBL10113283

SCHEMBL10113283

COC(=O)Cc1cccc(NC(=O)C2CCC(NS(=O)(=O)C(C)(C)C)CC2)c1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.48
NPY5R Q15761 1/20 0.47
GAA P10253 3/20 0.46
USP2 O75604 1/20 0.46
LMNA P02545 1/20 0.46
HPGD P15428 1/20 0.46
HTT P42858 1/20 0.46
EGLN1 Q9GZT9 1/20 0.45
ACKR3 P25106 5/20 0.42
ALDH1A1 P00352 1/20 0.42
MAPT P10636 3/20 0.42
TP53 P04637 1/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
MTNR1A P48039 1/20 0.41
MTNR1B P49286 1/20 0.41
GLA P06280 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13203822 1.00 SMN1; SMN2 (0.48) SMN1; SMN2NPY5RGAAUSP2LMNA
SCHEMBL10113291 0.90 SMN1; SMN2 (0.50) SMN1; SMN2NPY5RGAAUSP2LMNA
SCHEMBL13203824 0.90 SMN1; SMN2 (0.50) SMN1; SMN2NPY5RGAAUSP2LMNA
SCHEMBL10133142 0.87 SMN1; SMN2 (0.65) SMN1; SMN2NPY5RGAAUSP2LMNA
SCHEMBL10114077 0.86 GRIA2 (0.48) SMN1; SMN2GAAUSP2LMNAHPGD
SCHEMBL10133141 0.85 SMN1; SMN2 (0.50) SMN1; SMN2NPY5RGAAUSP2LMNA
SCHEMBL10113287 0.84 EGLN1 (0.48) SMN1; SMN2NPY5RGAAUSP2LMNA
SCHEMBL13203829 0.84 EGLN1 (0.48) SMN1; SMN2NPY5RGAAUSP2LMNA
SCHEMBL17090139 0.84 CRHR1 (0.38) NPY5RHTTMAPTTP53MEN1
SCHEMBL13203720 0.82 NPY5R (0.53) SMN1; SMN2NPY5RGAAUSP2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 US disclosed
US-20110039802-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2011-02-17 US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 US disclosed
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292500-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R SMN1; SMN2 2197/4885NPY5R 1/4885GAA 3316/4885
US-20110039802-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R SMN1; SMN2 2251/4885NPY5R 1/4885GAA 3472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.